Researchers report that a rapid liquid biopsy can speed diagnosis of Burkitt lymphoma in endemic areas. The study, published in March in Nature Medicine as “Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas”, was carried out in Tanzania and Uganda from August 2019 to July 2023 and involved children and young adults aged three to 25 years. Teams from the University of Oxford and Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam took part in the work.
The minimally invasive test uses a blood sample to detect tumour DNA associated with Burkitt lymphoma. In the study, liquid biopsy cut median diagnostic turnaround time from 46.8 days to 6.5 days and allowed 93.3 per cent of Burkitt lymphoma cases to be diagnosed within one week, compared with 40 per cent using tissue biopsy alone. The authors report high accuracy and say the test can be integrated into routine clinical workflows as a faster, complementary tool for earlier treatment decisions.
The researchers note practical challenges: the technology requires specialised sequencing infrastructure, reliable supply chains and trained personnel. They have worked to build local capacity so tests can be run within the region rather than relying on external laboratories. Project partners are planning clinical trials to evaluate implementation in routine healthcare and are engaging ministries of health about scale‑up. The project is part of the NIHR‑funded AI‑REAL consortium (Aggressive Infection‑Related East Africa Lymphoma).
Independent experts welcomed the study. Bruno Sunguya said it shows precision medicine research can be led from within low‑ and middle‑income countries, while Adedayo Joseph highlighted access, cost and local expertise as key factors for the test to benefit people across the continent.
Difficult words
- liquid biopsy — blood test that looks for tumour DNA
- endemic — regularly present in a particular regionendemic areas
- turnaround time — time between test and resultdiagnostic turnaround time
- tumour — an abnormal mass of cells in the bodytumour DNA
- integrate — to combine into an existing system or processintegrated
- infrastructure — the physical systems and equipment neededspecialised sequencing infrastructure
- supply chain — the system for moving goods to userssupply chains
- capacity — ability or resources to perform services locallylocal capacity
- consortium — a group of organisations working together
- precision medicine — medical approach tailored to individual patientsprecision medicine research
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How might faster diagnosis with liquid biopsy change treatment and outcomes for children and young adults in endemic areas?
- Based on the challenges named, which steps would you prioritise to build local capacity for these tests and why?
- What are the possible advantages and disadvantages of adding liquid biopsy into routine clinical workflows in the region?
Related articles
Sudan turns to AI as health system struggles
Sudan’s health system is under severe strain after an almost two‑year civil war. A senior health official says the country is using artificial intelligence to help provide care where normal services no longer reach, while shortages and attacks worsen the crisis.
People with disabilities in Kenya and Nigeria faced hardship during COVID-19
During the COVID-19 pandemic, people with disabilities in poor urban areas of Kenya and Nigeria had worse access to health care, lost income and faced higher costs. Researchers and advocates call for closer, accessible services and fair relief.
